Jbt Marel vs Middleby
JBTM and MIDD side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How JBTM and MIDD compare
Jbt Marel and Middleby are about the same size, with market caps of $6.5B and $6.1B.
On earnings, Jbt Marel is cheaper: it trades at 34.1× trailing earnings, against 159× for Middleby.
Jbt Marel grew revenue faster over the last twelve months (44.9% versus 9.2% for Middleby).
Jbt Marel keeps more of each dollar of sales as profit, with a net margin of 4.9% compared with 1.2% at Middleby.
Jbt Marel pays a dividend yielding 0.32%; Middleby does not pay one.
Jbt Marel scores higher on the StockData Score (12 against 7 for Middleby), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | JBTM | MIDD |
|---|---|---|
| Size and price | ||
| Market cap | $6.5B | $6.1B |
| Share price | $125.54 | $135.44 |
| Change, 1 year | −10.8% | 9.7% |
| Change, 5 years | −27.7% | −27.8% |
| Beta (5Y) | 0.94 | 1.07 |
| Employees | 12K | 2,393 |
| StockData Score | ||
| Total score | 12 (better) | 7 |
| Valuation score | 2 | 2 |
| Growth score | 2 (better) | 1 |
| Performance score | 0 | 1 (better) |
| Health score | 4 (better) | 3 |
| Dividend score | 4 (better) | 0 |
| Valuation | ||
| P/E | 34.1× (better) | 159× |
| P/S | 1.7× (better) | 1.9× |
| P/B | 1.5× (better) | 4.6× |
| EV/EBITDA | 28.0× | 10.9× (better) |
| P/FCF | 21.0× | 16.5× (better) |
| FCF yield | 4.8% | 6.1% (better) |
| Fair value | $115.41 | $151.36 |
| Margin of safety | −8.8% | 10.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 44.9% (better) | 9.2% |
| Revenue growth, 5Y average | 17.1% (better) | 5.0% |
| Profitability | ||
| Gross margin | 35.6% | 38.5% (better) |
| Operating margin | 7.3% | 18.8% (better) |
| Net margin | 4.9% (better) | 1.2% |
| FCF margin | 7.9% | 11.5% (better) |
| Return on equity | 4.3% (better) | 1.9% |
| Return on invested capital | 3.8% | 11.4% (better) |
| Financial health | ||
| Debt / equity | 0.38 (better) | 1.31 |
| Net debt / EBITDA | 5.46 | 2.32 (better) |
| Current ratio | 1.24 | 2.00 (better) |
| Altman Z-score | 2.03 | 4.07 (better) |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Dividend yield | 0.32% | – |
| Payout ratio | 10.9% | – |
| Years of dividend growth | 0 | – |
| Dividend growth, 5Y average | 0.00% | – |
| Buyback yield | – | 14.7% |
| Shareholder yield | 0.32% | 14.7% (better) |
| Ownership | ||
| Held by institutions | 103% | 105% |
| Held by insiders | 1.4% | 9.3% |
| Insider net buying, 12 months | −$4.3M | $15.1M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 8.0% | 3.7% |
Go deeper
- JBTM stock overview
- JBTM income statement
- JBTM valuation and score
- MIDD stock overview
- MIDD income statement
- MIDD valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.